Advertisement
Editorial|Articles in Press

Download started.

Ok

Depression after menopause and the use of menopausal hormone therapy

  • Irene Lambrinoudaki
    Affiliations
    Menopause Unit, Second Department of Obstetrics and Gynecology, National and Kapodistrian University of Athens, Aretaieio Hospital, Athens, Greece
    Search for articles by this author
  • Eleni Armeni
    Correspondence
    Corresponding author at: Fleet Road 88, NW3 2QT London, UK.
    Affiliations
    Menopause Unit, Second Department of Obstetrics and Gynecology, National and Kapodistrian University of Athens, Aretaieio Hospital, Athens, Greece

    Royal Free Hospital NHS Foundation Trust, University College London, Medical School, London, UK
    Search for articles by this author
Published:December 23, 2022DOI:https://doi.org/10.1016/j.maturitas.2022.12.005
Depression after menopause and the use of menopausal hormone therapy
Previous ArticleDesign thinking and clinical living labs: Two complementary approaches for addressing complex health challenges in geriatric medicine
Next ArticleDeveloping bespoke antimicrobials to combat antimicrobial resistance in low- and middle-income countries: A critical appraisal of clinical utility in the elderly
      Perimenopause is a window of vulnerability for the development of mood disorders which involve both depressive symptoms or even episodes of depression. The experience of an episode of depression during perimenopause usually is a recurrence of prior depression rather than a new-onset depressive disorder [
      • Maki P.M.
      • Kornstein S.G.
      • Joffe H.
      • Bromberger J.T.
      • Freeman E.W.
      • Athappilly G.
      • Bobo W.V.
      • Rubin L.H.
      • Koleva H.K.
      • Cohen L.S.
      • Soares C.N.
      Guidelines for the evaluation and treatment of perimenopausal depression: summary and recommendations.
      Menopause. 2018; 25: 1069-1085
      ]. The risk for depression decreases within two to four years after the last menstrual period, especially for women with no previous history of depression. During perimenopause, the use of menopausal hormone therapy (MHT) may improve depressive symptoms [
      • Maki P.M.
      • Kornstein S.G.
      • Joffe H.
      • Bromberger J.T.
      • Freeman E.W.
      • Athappilly G.
      • Bobo W.V.
      • Rubin L.H.
      • Koleva H.K.
      • Cohen L.S.
      • Soares C.N.
      Guidelines for the evaluation and treatment of perimenopausal depression: summary and recommendations.
      Menopause. 2018; 25: 1069-1085
      ,
      • Stute P.
      • Spyropoulou A.
      • Karageorgiou V.
      • Cano A.
      • Bitzer J.
      • Ceausu I.
      • Chedraui P.
      • Durmusoglu F.
      • Erkkola R.
      • Goulis D.G.
      • Hirschberg A.Lindén
      • Kiesel L.
      • Lopes P.
      • Pines A.
      • Rees M.
      • van Trotsenburg M.
      • Zervas I.
      • Lambrinoudaki I.
      Management of depressive symptoms in peri- and postmenopausal women: EMAS position statement.
      Maturitas. 2020; 131: 91-101
      ].

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Maturitas
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Register: Create an account
      Institutional Access: Sign in to ScienceDirect

      References

        • Maki P.M.
        • Kornstein S.G.
        • Joffe H.
        • Bromberger J.T.
        • Freeman E.W.
        • Athappilly G.
        • Bobo W.V.
        • Rubin L.H.
        • Koleva H.K.
        • Cohen L.S.
        • Soares C.N.
        Guidelines for the evaluation and treatment of perimenopausal depression: summary and recommendations.
        Menopause. 2018; 25: 1069-1085
        View in Article
        • Stute P.
        • Spyropoulou A.
        • Karageorgiou V.
        • Cano A.
        • Bitzer J.
        • Ceausu I.
        • Chedraui P.
        • Durmusoglu F.
        • Erkkola R.
        • Goulis D.G.
        • Hirschberg A.Lindén
        • Kiesel L.
        • Lopes P.
        • Pines A.
        • Rees M.
        • van Trotsenburg M.
        • Zervas I.
        • Lambrinoudaki I.
        Management of depressive symptoms in peri- and postmenopausal women: EMAS position statement.
        Maturitas. 2020; 131: 91-101
        View in Article
        • Wium-Andersen M.K.
        • Jørgensen T.S.H.
        • Halvorsen A.H.
        • Hartsteen B.H.
        • Jørgensen M.B.
        • Osler M.
        Association of hormone therapy with depression during menopause in a cohort of Danish women.
        JAMA Netw. Open. 2022; 5e2239491
        View in Article
        • Natari R.B.
        • Clavarino A.M.
        • McGuire T.M.
        • Dingle K.D.
        • Hollingworth S.A.
        The bidirectional relationship between vasomotor symptoms and depression across the menopausal transition: a systematic review of longitudinal studies.
        Menopause. 2018; 25: 109-120
        View in Article
        • Lambrinoudaki I.
        • Armeni E.
        • Goulis D.
        • Bretz S.
        • Ceausu I.
        • Durmusoglu F.
        • Erkkola R.
        • Fistonic I.
        • Gambacciani M.
        • Geukes M.
        • Hamoda H.
        • Hartley C.
        • Hirschberg A.L.
        • Meczekalski B.
        • Mendoza N.
        • Mueck A.
        • Smetnik A.
        • Stute P.
        • van Trotsenburg M.
        • Rees M.
        Menopause, wellbeing and health: a care pathway from the european menopause and andropause society.
        Maturitas. 2022; 163: 1-14
        View in Article
        • Shea A.K.
        • Sohel N.
        • Gilsing A.
        • Mayhew A.J.
        • Griffith L.E.
        • Raina P.
        Depression, hormone therapy, and the menopausal transition among women aged 45 to 64 years using Canadian longitudinal study on aging baseline data.
        Menopause. 2020; 27: 763-770
        View in Article

      Article info

      Publication history

      Published online: December 23, 2022
      Accepted: December 15, 2022
      Received: December 6, 2022

      Publication stage

      In Press Journal Pre-Proof

      Identification

      DOI: https://doi.org/10.1016/j.maturitas.2022.12.005

      Copyright

      © 2022 Elsevier B.V. All rights reserved.

      ScienceDirect

      Access this article on ScienceDirect
      We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the for this site.
      Copyright © 2023 Elsevier Inc. except certain content provided by third parties. The content on this site is intended for healthcare professionals.


      RELX